First-in-human Phase 1/2 trial of DS-3790A (CD37-targeting DXd-ADC) in hematological malignancies

Phase 2, randomised, open-label trial of DS3790a in hematopoietic malignancies (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability – dose-limiting toxicities, treatment-emergent adverse events, serious adverse events, adverse events of special interest, and deaths, Complete response rate by blinded independent central review (Cohort A Randomization Optimization Phase and Cohort A Phase 2) and 1 more. Planned start Apr 2026; status: authorised.